Anti-VEGF Cancer Therapy in Nephrology Practice
Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established....
Saved in:
Main Author: | Hassan Izzedine |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | International Journal of Nephrology |
Online Access: | http://dx.doi.org/10.1155/2014/143426 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy
by: Caroline Hilmi, et al.
Published: (2012-01-01) -
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians
by: Pearse A. Keane, et al.
Published: (2012-01-01) -
Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
by: Filipe Mira, et al.
Published: (2017-01-01) -
Variation in Assessing Renal Allograft Rejection: A National Assessment of Nephrology Practice
by: John Peabody, et al.
Published: (2019-01-01) -
Anti-VEGF Treatment Strategies for Wet AMD
by: Jaclyn L. Kovach, et al.
Published: (2012-01-01)